Biotechnology

Henlius Forecasts Profit in 2023: Achieving first full year of profitability, and ushering in a new phase of high-quality development

SHANGHAI, March 4, 2024 /PRNewswire/ -- Henlius (2696.HK) released a positive profit forecast. Based on the preliminary assessment of the unaudited consolidated management accounts for the year ended31 December, 2023 (the "Reporting Period") and the information currently available to the Board,it...

2024-03-04 21:19 604

Hybribio Calls for Raising International HPV Awareness

GUANGZHOU, China, March 4, 2024 /PRNewswire/ -- March 4th 2024 marks the 7th International HPV Awareness Day, a global campaign proposed by the International Papillomavirus Society (IPVS) since 2018. This year, the theme is One Less Worry. On this special day, Hybribio (300639.SZ) calls for raisi...

2024-03-04 18:47 318

Results from the Clinical Trial of Qilu Pharmaceutical's Novel Anticancer Agent Iparomlimab and Tuvonralimab (QL1706) Featured in Oral Presentation at the ESGO Annual Meeting

JINAN, China, March 4, 2024 /PRNewswire/ -- The European Society of Gynecological Oncology (ESGO) 2024 Conference has recently made selected abstracts available online. The abstract (abstract # 251) that details results from the Phase II clinical trial (DUBHE-C-206) evaluating the efficacy and s...

2024-03-04 16:53 741

Thermo Fisher Scientific to Inaugurate New Office, Marking Milestone Expansion in Indonesia

Company to support advancements in country's science and technology sector, with a focus on progressing healthcare, environmental solutions, and food safety JAKARTA, Indonesia, March. 1, 2024 /PRNewswire/ -- Thermo Fisher Scientific, the world leader in serving science, will significantly expand ...

2024-03-01 10:30 4189

Innovent Announces First Participant Dosed in a Phase I Study of IBI3002 (an anti-IL-4Rα/TSLP bispecific antibody) in Australia

ROCKVILLE, Md. and SUZHOU, China, March 1, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and ...

2024-03-01 08:00 2002

Metabolon Unveils New Integrated Bioinformatics Platform

Metabolon's cutting-edge bioinformatics platform and unique knowledge base will enable customers to leverage the company's extensive biochemistry experience MORRISVILLE, N.C., Feb. 29, 2024 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide var...

2024-02-29 20:58 1333

Medidata and Sanofi Vaccines Extend Collaboration to Improve Patient Centricity and Trial Efficiency

Collaboration will harness Medidata Electronic Clinical Outcome Assessment (eCOA) for remote patient engagement and real-time data capture SINGAPORE, Feb. 29, 2024 /PRNewswire/ -- Medidata , a Dassault Systèmes company and leading provider of clinical trial solutions to ...

2024-02-29 17:40 1224

MGI Tech & Juntendo University: Changing the Landscape and Unlocking Answers for Patients with Rare Diseases

TOKYO, Feb. 29, 2024 /PRNewswire/ -- Rare diseases have historically been overlooked because they affect relatively few people. While they are identified and addressed differently around the world, there are over known 6,000 rare diseases – characterized by a wide range of disorders and symptoms...

2024-02-29 09:00 1656

Skyhawk Therapeutics Has Advanced to the Multiple Ascending Dose Portion of its Phase 1 Study evaluating SKY-0515, a RNA-Targeting Small Molecule for Huntington's Disease

SKY-0515 is a small molecule RNA splicing modifier developed through the company's novel SKYSTAR® platform. Having successfully advanced through single asending dose, SKY-0515 is advancing into the Multiple Ascending Dose portion of its phase 1 study. Huntington's disease is a fatal neurological ...

2024-02-28 21:32 1064

RRD International is now RRD Biopharma Development

RRD Biopharma Development is the dynamic new brand of RRD International. Launched to reflect the company's unique approach to drug development through its successful Product Development Team model. ROCKVILLE, Md., Feb. 28, 2024 /PRNewswire/ -- RRD International has announced today that it launch...

2024-02-28 21:00 1104

BioCina and NovaCina Forge Strategic Alliance to Offer Biologics Developers Integrated Drug Substance and Drug Product Solutions

ADELAIDE, South Australia, and PERTH, Western Australia, Feb. 27, 2024 /PRNewswire/ -- BioCina Pty Ltd., a global end-to-end biologics Contract Development and Manufacturing Organisation (CDMO), and NovaCina Pty Ltd., a global fill-and-finish CDMO, announced a strategic partnership to provide in...

2024-02-28 02:30 929

New Models of PENTAX Medical i20c Video Endoscope Series Obtain CE Marks

TOKYO, Feb. 27, 2024 /PRNewswire/ -- PENTAX Medical, a division of HOYA Group, have obtained CE marks for new models of PENTAX Medical i20c Video Endoscope Series - PENTAX Medical Video Colonoscope EC34-i20c, PENTAX Medical Video Upper GI Scope EG27-i20c and R/L Knob Adaptor OE-B17.

2024-02-27 17:00 865

Jenny Zheng joins Illumina as Senior Vice President and General Manager of Greater China

SHANGHAI, Feb. 27, 2024 /PRNewswire/ -- On February 26, 2024, Illumina Inc. (NASDAQ: ILMN) a global leader in DNA sequencing and array-based technologies, announced thatJenny Zheng joins Illumina as Senior Vice President and General Manager ofGreater China, and a member of the global executive ma...

2024-02-27 16:09 968

Sengenics Corporation Announces Key Distributor in China

Sengenics Partners with Shanghai Universal Biotech Co., Ltd. (UniV) to Expand Reach of Immunoprofiling Products and Services inChina BOSTON, Feb. 27, 2024 /PRNewswire/ -- Sengenics Corporation LLC, a pioneer in the field of immunoproteomic biomarker discovery, proudly announces that it has enter...

2024-02-27 08:30 1129

Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis

SHANGHAI, China and SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK) and Kezar Life Sciences, Inc. (Nasdaq: KZR) announced today that the Center for Drug Evaluation (CDE) ofChina's National Medical Products Administration (NMPA) approved Kezar's investig...

2024-02-27 07:14 1017

Neomorph Announces Multi-Target Collaboration with Novo Nordisk to Discover Novel Molecular Glue Degraders for Cardiometabolic and Rare Diseases

* Collaboration leverages Neomorph's leading molecular glue discovery platform and Novo Nordisk's extensive expertise in cardiometabolic and rare diseases * Total potential deal value of $1.46B across multiple targets SAN DIEGO, Feb. 27, 2024 /PRNewswire/ -- Neomorph, Inc. today announced it ...

2024-02-27 01:06 1018

Everest Medicines' Partner Pfizer Announces European Commission Approves VELSIPITY® for Patients with Moderately to Severely Active Ulcerative Colitis

--VELSIPITY is the first and only oral advanced ulcerative colitis therapy approved for use in patients 16 years of age or older in the EU-- SHANGHAI, Feb. 22, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company")'s partner Pfizer Inc. (NYSE: PFE) announced that the ...

2024-02-22 08:59 1347

Findings of a Phase III Clinical Study of Sanbexin® Sublingual Tablets Published in JAMA

NANJING, China, Feb. 21, 2024 /PRNewswire/ -- On February 19, 2024, the Journal of American Medical Association•Neurology (JAMA NEUROLOGY, IF: 29.0) published online the key findings of a phase III clinical study (NCT04950920) (the "TASTE-SL Study") investigating Sanbexin® (a combination of edara...

2024-02-21 12:26 1704

Everest Medicines' Licensing Partner Venatorx Pharmaceuticals Announces Publication of Positive Results from Cefepime-Taniborbactam's Phase 3 CERTAIN-1 Study in New England Journal of Medicine

--Cefepime-taniborbactam was superior to meropenem for the composite efficacy endpoint with composite efficacy sustained at late follow-up visit-- SHANGHAI, Feb. 21, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK)'s licensing partner, Venatorx Pharmaceuticals announced that The New England ...

2024-02-21 09:00 2663

HKUST Neuroscientists Develop Highly Accurate Universal Diagnostic Blood Test for Alzheimer's Disease and Mild Cognitive Impairment

At a glance: * Remarkably high accuracy rate – over 96% for AD and 87% for MCI; * Applicable across diverse ethnic populations, including Chinese and European; * Enables early detection of AD and subsequent progression; * Captures multiple AD-associated biological pathways; * A game-chan...

2024-02-19 20:18 1478
12345 ... 163